154 related articles for article (PubMed ID: 33986254)
1. Targeting epigenetic modulation of cholesterol synthesis as a therapeutic strategy for head and neck squamous cell carcinoma.
Xu X; Chen J; Li Y; Yang X; Wang Q; Wen Y; Yan M; Zhang J; Xu Q; Wei Y; Chen W; Wang X
Cell Death Dis; 2021 May; 12(5):482. PubMed ID: 33986254
[TBL] [Abstract][Full Text] [Related]
2. Targeting of EZH2 inhibits epithelial‑mesenchymal transition in head and neck squamous cell carcinoma via regulating the STAT3/VEGFR2 axis.
Zhao M; Hu X; Xu Y; Wu C; Chen J; Ren Y; Kong L; Sun S; Zhang L; Jin R; Zhou X
Int J Oncol; 2019 Nov; 55(5):1165-1175. PubMed ID: 31545422
[TBL] [Abstract][Full Text] [Related]
3. Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation.
Gannon OM; Merida de Long L; Endo-Munoz L; Hazar-Rethinam M; Saunders NA
Clin Cancer Res; 2013 Jan; 19(2):428-41. PubMed ID: 23186778
[TBL] [Abstract][Full Text] [Related]
4. Targeting EZH2 regulates tumor growth and apoptosis through modulating mitochondria dependent cell-death pathway in HNSCC.
Zhou X; Ren Y; Kong L; Cai G; Sun S; Song W; Wang Y; Jin R; Qi L; Mei M; Wang X; Kang C; Li M; Zhang L
Oncotarget; 2015 Oct; 6(32):33720-32. PubMed ID: 26378043
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma.
Cao W; Feng Z; Cui Z; Zhang C; Sun Z; Mao L; Chen W
Cancer; 2012 Jun; 118(11):2858-71. PubMed ID: 21989926
[TBL] [Abstract][Full Text] [Related]
6. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
[TBL] [Abstract][Full Text] [Related]
7. Loss of TP63 Promotes the Metastasis of Head and Neck Squamous Cell Carcinoma by Activating MAPK and STAT3 Signaling.
Lakshmanachetty S; Balaiya V; High WA; Koster MI
Mol Cancer Res; 2019 Jun; 17(6):1279-1293. PubMed ID: 30910837
[TBL] [Abstract][Full Text] [Related]
8. EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity.
Chang JW; Gwak SY; Shim GA; Liu L; Lim YC; Kim JM; Jung MG; Koo BS
Oral Oncol; 2016 Jan; 52():66-74. PubMed ID: 26604082
[TBL] [Abstract][Full Text] [Related]
9. Nuclear localization signal-enhanced RNA interference of EZH2 and Oct4 in the eradication of head and neck squamous cell carcinoma-derived cancer stem cells.
Lo WL; Chien Y; Chiou GY; Tseng LM; Hsu HS; Chang YL; Lu KH; Chien CS; Wang ML; Chen YW; Huang PI; Hu FW; Yu CC; Chu PY; Chiou SH
Biomaterials; 2012 May; 33(14):3693-709. PubMed ID: 22361100
[TBL] [Abstract][Full Text] [Related]
10. Blockade of deubiquitinating enzyme PSMD14 overcomes chemoresistance in head and neck squamous cell carcinoma by antagonizing E2F1/Akt/SOX2-mediated stemness.
Jing C; Duan Y; Zhou M; Yue K; Zhuo S; Li X; Liu D; Ye B; Lai Q; Li L; Yao X; Wei H; Zhang W; Wu Y; Wang X
Theranostics; 2021; 11(6):2655-2669. PubMed ID: 33456565
[TBL] [Abstract][Full Text] [Related]
11. Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer.
Zhou L; Mudianto T; Ma X; Riley R; Uppaluri R
Clin Cancer Res; 2020 Jan; 26(1):290-300. PubMed ID: 31562203
[TBL] [Abstract][Full Text] [Related]
12. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
[TBL] [Abstract][Full Text] [Related]
13. Distinct epigenetic profiling in head and neck squamous cell carcinoma stem cells.
Furusawa J; Zhang H; Vural E; Stone A; Fukuda S; Oridate N; Fang H; Ye Y; Suen JY; Fan CY
Otolaryngol Head Neck Surg; 2011 Jun; 144(6):900-9. PubMed ID: 21493336
[TBL] [Abstract][Full Text] [Related]
14. Molecular dissection of the oncogenic role of ETS1 in the mesenchymal subtypes of head and neck squamous cell carcinoma.
Gluck C; Glathar A; Tsompana M; Nowak N; Garrett-Sinha LA; Buck MJ; Sinha S
PLoS Genet; 2019 Jul; 15(7):e1008250. PubMed ID: 31306413
[TBL] [Abstract][Full Text] [Related]
15. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
16. Aberrant Epigenetic Regulation in Head and Neck Cancer Due to Distinct EZH2 Overexpression and DNA Hypermethylation.
Mochizuki D; Misawa Y; Kawasaki H; Imai A; Endo S; Mima M; Yamada S; Nakagawa T; Kanazawa T; Misawa K
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30469511
[TBL] [Abstract][Full Text] [Related]
17. Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma.
Yun M; Choi AJ; Lee YC; Kong M; Sung JY; Kim SS; Eun YG
J Exp Clin Cancer Res; 2018 Oct; 37(1):264. PubMed ID: 30376862
[TBL] [Abstract][Full Text] [Related]
18. Silencing of long non-coding RNA LINC00520 promotes radiosensitivity of head and neck squamous cell carcinoma cells.
Li J; Liu X; Nan S; Xu C
Free Radic Res; 2020 Apr; 54(4):254-270. PubMed ID: 32462956
[TBL] [Abstract][Full Text] [Related]
19. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
20. STAT3/HOTAIR Signaling Axis Regulates HNSCC Growth in an EZH2-dependent Manner.
Sun S; Wu Y; Guo W; Yu F; Kong L; Ren Y; Wang Y; Yao X; Jing C; Zhang C; Liu M; Zhang Y; Zhao M; Li Z; Wu C; Qiao Y; Yang J; Wang X; Zhang L; Li M; Zhou X
Clin Cancer Res; 2018 Jun; 24(11):2665-2677. PubMed ID: 29540490
[No Abstract] [Full Text] [Related]
[Next] [New Search]
